Look back at pharma news in week to October 26

28 October 2018

By Barbara Obstoj-Cardwell. Editor

Featured regulatory news last week included US Food and Drug Administration approval for Sanofi and Regeneron’s Dupixent in the all important asthma indication. Among new clinical trial data, there was disappointment for Merrimack Pharma’s MM-121 in a lung cancer study, and Eisai and Biogen presented new data on their Alzheimer’s candidate BAN2401, but failed to win over doubters. On the deal-making front, AstraZeneca’s decision to expand its collaboration with France’s Innate Pharma in immuno-oncology with candidate monalizumab suggests a turnaround in the latter’s fortunes. Finally, Amgen announced a massive 60% cut in the list price of its cholesterol drug Repatha.

Dupixent gets best in class label in asthma, still on the way to $7bn+

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK